Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:7
  • preuzimanja u poslednjih 30 dana:4
članak: 1 od 1  
Back povratak na rezultate
Srce i krvni sudovi
2016, vol. 35, br. 2, str. 60-64
jezik rada: engleski
vrsta rada: prikaz slučaja
doi:10.5937/siks1602060N


Dobar efekat niskih doza blokatora kalcijumskih kanala kod bolesnice sa idiopatskom plućnom hipertenzijom
aUniverzitet u Beogradu, Medicinski fakultet
bClinical Center of Serbia, Clinic of Cardiology, Belgrade
cInstitute of Public Health Sabac, Sabac
dUniversity of Belgrade, School of Medicine, Belgrade + Clinical Center of Serbia, Clinic of Cardiology, Belgrade

e-adresa: olganedeljkovic@gmail.com

Sažetak

Uvod: Plućna hipertenzija je hemodinamsko i patofiziološko stanje povećanog srednjeg arterijskog pritiska u plućnoj arteriji, preko 25mmHg u miru, procenjenog kateterizacijom desnog srca. Prikaz bolesnika: Pacijentkinja starosti 44 godine dolazi na kardiološki pregled 13 godina nakon što joj je postavljena dijagnoza primarne plućne hipertenzije. Na koronarnim arterijama nisu viđene promene. Isključeno je postojanje sistemske bolesti vezivnog tkiva. Od tada do danas je na istoj terapiji niskim dozama antagonista Ca (Nifelat 2x10mg) uz oralnu antikoagulantnu terapiju, stabilnog stanja, bez progresije tegoba. Zamara se isključivo pri većem fizičkom naporu, ponekad oseća ubrzani srčani rad i nesvesticu. Objektivno čujan sistolni šum uz naglašen drugi ton nad plućnom arterijom, elektrokardiogram sinusni ritam, inkompletni blok desne grane. Ehokardiografski pregled pokazuje znake plućne hipertenzije. Zaključak: Mali broj bolesnika sa plućnom hipertenzijom koja se odlikuje vazokonstriktornim svojstvima imaju dobru prognozu na terapiji visokim dozama kalcijumskih blokatora dok naša pacijentkinja ima dugogodišnji stabilan tok bolesti na niskoj dozi Ca blokatora.

Ključne reči

primarna plućna hipertenzija; blokatori Ca kanala; kateterizacija; ehokardiografija

Reference

*** (2012) What is pulmonary hypertension?. American Heart Association, Jun, http://www.heart.org/HEARTORG/Conditions/HighBloodPressure/AboutHighBlood-Pressure/What-is-Pulmonary-Hypertension_UCM_301792_Article.jsp
Abe, K., Shimokawa, H., Morikawa, K., Uwatoku, T., Oi, K., Matsumoto, Y., Hattori, T., Nakashima, Y., Kaibuchi, K., Sueishi, K., Takeshit, A. (2004) Long-Term Treatment With a Rho-Kinase Inhibitor Improves Monocrotaline-Induced Fatal Pulmonary Hypertension in Rats. Circulation Research, 94(3): 385-393
Badesch, D.B., Raskob, G.E., Elliott, C.G., i dr. (2010) Pulmonary hypertension: Baseline characteristics from the REVEAL Registry. Chest, 137, 376-387
Chin, K.M., Rubin, L.J. (2008) Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 51(16): 1527-1538
Galiè, N., Hoeper, M.M., Humbert, M., Torbicki, A., Vachiery, J.L., Barberaet, J.A., i dr. (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: The task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS),. Eur Heart J., 30(20), str. 2493-537
Galiè, N., Manes, A., Negro, L., Palazzini, M., Bacchi-Reggiani, M.L., Branzi, A. (2009) A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J., 30(4), str. 394-403
Guignabert, C., Izikki, M., Tu, L.I., Li, Z., Zadigue, P., Barlier-Mur, A., Hanoun, N., Rodman, D., Hamon, M., Adnot, S., Eddahibi, S. (2006) Transgenic Mice Overexpressing the 5-Hydroxytryptamine Transporter Gene in Smooth Muscle Develop Pulmonary Hypertension. Circulation Research, 98(10): 1323-1330
Humbert, M., Sitbon, O., Chaouat, A., Bertocchi, M., Habib, G., Gressin, V., Yaici, A., Weitzenblum, E., Cordier, J., Chabot, F., Dromer, C., Pison, C., Reynaud-Gaubert, M., Haloun, A. (2006) Pulmonary Arterial Hypertension in France. American Journal of Respiratory and Critical Care Medicine, 173(9): 1023-1030
Lapa, M., Dias, B., Jardim, C., Fernandes, C.J.C., Dourado, P.M.M., Figueiredo, M., Farias, A., Tsutsui, J., Terra-Filho, M., Humbert, M., Souza, R. (2009) Cardiopulmonary Manifestations of Hepatosplenic Schistosomiasis. Circulation, 119(11): 1518-1523
McLaughlin, V.V., Shillington, A. (2002) Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy. Circulation, 106(12): 1477-1482
McLaughlin, V.V., Archer, S.L., Badesch, D.B., Barst, R.J., Farber, H.W., Lindner, J.R., Mathier, M.A., McGoon, M.D., Park, M.H., Rosenson, R.S., Rubin, L.J., Tapson, V.F., Varga, J. (2009) ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. Circulation, 119(16): 2250-2294
Mukerjee, D. (2003) Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Annals of the Rheumatic Diseases, 62(11): 1088-1093
Oudiz, R. (2007) Pulmonary hypertension. Primary, eMedicine, August, Available at URL: http://emedicine.medscape.com/article/301450-overview
Peacock, A. (2003) Treatment of pulmonary hypertension. BMJ, 326(7394): 835-836
Petkov, V., Mosgoeller, W., Ziesche, R., Raderer, M., Stiebellehner, L., Vonbank, K., Funk, G., Hamilton, G., Novotny, C., Burian, B., Block, L. (2003) Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. Journal of Clinical Investigation, 111(9): 1339-1346
Porhownik, N.R., Bshouty, Z. (2007) Pulmonary arterial hypertension: A serious problem. Perspect Cardiol, 23: 33-40
Rich, S., Dantzker, D.R., Ayres, S.M., Bergofsky, E.H., Brundage, B.H., Detre, K.M., Fishman, A.P., Goldring, R.M., Groves, B.M., Koerner, S.K. (1987) Primary pulmonary hypertension. A national prospective study. Ann Intern Med, 107(2): 216-23
Rich, S., Kaufmann, E., Levy, P.S. (1992) The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension. New England Journal of Medicine, 327(2): 76-81
Rubin, L.J., Badesch, D.B. (2005) Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med, 143, str. 282-92
Rudarakanchana, N., Trembath, R.C., Morrell, N.W. (2001) New insights into the pathogenesis and treatment of primary pulmonary hypertension. Thorax, 56, str. 888-90
Runo, J.R., Loyd, J.E. (2003) Primary pulmonary hypertension. Lancet, 361(9368): 1533-1544
Schermuly, R.T. (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. Journal of Clinical Investigation, 115(10): 2811-2821
Simonneau, G., Robbins, I.M., Beghetti, M., Channick, R.N., Delcroix, M., Denton, C.P., Elliott, C., Gaine, S.P., Gladwin, M.T., Jing, Z., Krowka, M.J., Langleben, D., Nakanishi, N., Souza, R. (2009) Updated clinical classification of pulmonary hypertension. Journal of the American College of Cardiology, 54(1 Suppl): S43-54
Sitbon, O., Humbert, M., Jäis, X. (2005) Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension. ACC Current Journal Review, 14(10): 30
Thenappan, T., Shah, S.J., Rich, S., Gomberg-Maitland, M. (2007) A USA-based registry for pulmonary arterial hypertension: 1982 2006. European Respiratory Journal, 30(6): 1103-1110
Yigla, M., Kramer, M.R., Bendayan, D., i dr. (2004) Unexplained severe pulmonary hypertension in the elderly: report on 14 patients. Isr Med Assoc J, 6: 78-81